On May 17, 2024, Regeneron filed a second infringement litigation against Celltrion's proposed EYLEA® (aflibercept) biosimilar CT-P42, Case No. 1:24-cv-00053 (N.D.W. Va.).
United States - Patent - FDA Approves First Two Interchangeable EYLEA® Biosimilars – Biocon's Yesafili™ (Aflibercept-jbvf) And Samsung Bioepis's Opuviz™ (Aflibercept-yszy) mondaq.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mondaq.com Daily Mail and Mail on Sunday newspapers.
The First Biosimilar Disputes at the Unified Patent Court (UPC) | Venable LLP jdsupra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jdsupra.com Daily Mail and Mail on Sunday newspapers.
Regeneron Files Second BPCIA Complaint Against Celltrion's Proposed EYLEA® Biosimilar CT-P42 | Venable LLP jdsupra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jdsupra.com Daily Mail and Mail on Sunday newspapers.
FDA Approves First Two Interchangeable EYLEA® Biosimilars – Biocon's Yesafili™ (aflibercept-jbvf) and Samsung Bioepis's Opuviz™ (aflibercept-yszy) | Venable LLP jdsupra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jdsupra.com Daily Mail and Mail on Sunday newspapers.